ACC Action Center
Welcome to the ACC Action Center, bringing you the latest updates from the American College of Cardiology’s Annual Scientific Session & Expo, hosted in partnership with the World Congress of Cardiology. This collection will highlight emerging clinical data and explore the latest practice-changing advances in the field of cardiology.
Episodes 1-15 of 47
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
CardiologyAnalysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
CardiologyEffect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
CardiologyKidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
CardiologyMode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
CME/CEFAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
- advertisement
NYHA FC and Finerenone Response: Clinical Trial Insights
CardiologyNYHA FC and Finerenone Response: Clinical Trial Insights
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC Action CenterEffects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC Action CenterTargeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC Action CenterLong-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Promising results for self-expanding TAVR device in trial with mostly women
ACC Action CenterPromising results for self-expanding TAVR device in trial with mostly women
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC Action CenterAngiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
- advertisement
Preventive PCI versus optimal medical therapy only for vulnerable plaques
ACC Action CenterPreventive PCI versus optimal medical therapy only for vulnerable plaques
Promising results for APOC3 ASO in familial chylomicronemia syndrome
ACC Action CenterPromising results for APOC3 ASO in familial chylomicronemia syndrome
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC Action CenterIncreasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
